(2-氧代丙基)氨基甲酸叔丁酯 | 170384-29-9

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酮
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2-氧代丙基)氨基甲酸叔丁酯
• 中文别名: 1-(Boc-氨基)-2-丙酮；N-Boc-1-氨基丙酮；N-BOC-1-氨基丙酮；(2-氧代-丙基)-氨基甲酸叔丁酯
• 英文名称: tert-butyl (2-oxopropyl)carbamate
• 英文别名: tert-butyl N-(2-oxopropyl)carbamate
• CAS: 170384-29-9
• 化学式: C₈H₁₅NO₃
• 分子量: 173.212
• InChiKey: OZGMUQGCAFEQOX-UHFFFAOYSA-N

物化性质

• 熔点：
  48-49 °C
• 沸点：
  80-85 °C(Press: 0.1 Torr)
• 密度：
  1.018±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 危险性防范说明：
  P273
• 危险性描述：
  H302,H412
• 储存条件：
  存储条件：2-8°C，干燥密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (2-Oxopropyl)carbamic acid tert-butyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H412: Harmful to aquatic life with long lasting effects
P273: Avoid release to the environment

---

Section 3. Composition/information on ingredients.
Ingredient name: (2-Oxopropyl)carbamic acid tert-butyl ester
CAS number: 170384-29-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H15NO3
Molecular weight: 173.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2-氧代丙基)氨基甲酸叔丁酯 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 (1R,2R)-(-)-N-(对甲基苯磺酰基)-1,2-二苯基乙二胺 氢氧化钾 、 甲酸 、 三乙胺 、 对甲苯磺酰氯 作用下， 以 四氢呋喃 为溶剂， 反应 26.0h， 生成 (R)-2-甲基氮丙啶-1-羧酸叔丁酯
  参考文献：
  名称：

  Enantioselective synthesis of β-hydroxy amines and aziridines using asymmetric transfer hydrogenation of α-amino ketones

  摘要：

  α-氨基酮的对映选择性转移氢化是一种有效的方法，用于手性合成β-羟基胺和氮丙啶。

  DOI：

  10.1039/b102895m
• 作为产物：
  描述：

  叔丁氧基 N-氨基甲酸丙烯 在 叔丁基过氧化氢 、 silver hexafluoroantimonate 、 二氯[2-(4,5-二氢-2-噁唑基)喹啉]钯(II) 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.5h， 以411 mg的产率得到(2-氧代丙基)氨基甲酸叔丁酯
  参考文献：
  名称：

  受保护的烯丙胺的催化剂控制的瓦克型氧化

  摘要：

  相反：利用 [Pd(quinox)]-TBHP 催化剂体系，受保护的烯丙胺被氧化，具有高选择性，生成甲基酮产物。这与通过底物控制的 Tsuji-Wacker 氧化获得的结果相反，这突出了此处介绍的催化剂控制系统（参见方案）。各种 N 保护基团以高酮选择性进行选择性氧化。TBHP=叔丁基过氧化氢。

  DOI：

  10.1002/anie.201004156
• 作为试剂：
  描述：

  2-(aminomethyl)-4-(tert-butyl)-6-(6-(trifluoromethyl)pyridin-3-yl)phenol hydrochloride 、 、 碳酸氢钠 、 硼氢化钠 在 Sodium sulfate-III 、 (2-氧代丙基)氨基甲酸叔丁酯 、 乙醇 、 氯化铵 、 乙酸乙酯 作用下， 以 乙酸乙酯 为溶剂， 反应 73.0h， 以to give tert-butyl (2-((5-(tert-butyl)-2-hydroxy-3-(6-(trifluoromethyl)pyridin-3-yl)benzyl)amino)propyl)carbamate (500 mg, 67%) as a white solid的产率得到tert-butyl (2-((5-(tert-butyl)-2-hydroxy-3-(6-(trifluoromethyl)pyridin-3-yl)benzyl)amino)propyl)carbamate
  参考文献：
  名称：

  Heteroaryl derivatives and uses thereof

  摘要：

  本发明涉及抗疟化合物及其对疟原虫属Plasmodium的使用，包括耐药性Plasmodia菌株。本发明还涉及含有这种化合物的组合物以及制造这种化合物的过程。

  公开号：

  US09409893B2

文献信息

• 苯并咪唑类衍生物及其药学用途
  申请人：上海美悦生物科技发展有限公司

  公开号：CN110343089A

  公开（公告）日：2019-10-18

  本发明公开了一种苯并咪唑类衍生物及其药学用途，特别是公开了一种如式I所示的苯并咪唑类衍生物及其在制备治疗和/或预防血栓形成或血栓栓塞病症的药物中的用途。
• [EN] AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS<br/>[FR] AMINOPYRROLOTRIAZINES EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019147782A1

  公开（公告）日：2019-08-01

  The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

  该公开涉及到公式I的化合物，这些化合物可用作激酶调节剂，包括RIPK1调节。该公开还提供了制备和使用这些化合物的方法，例如在涉及坏死或炎症以及其他适应症的治疗中使用。
• IONIZABLE CATIONIC LIPID FOR RNA DELIVERY
  申请人：Arcturus Therapeutics, Inc.

  公开号：US20180169268A1

  公开（公告）日：2018-06-21

  What is described is a compound of formula I consisting of a compound in which R 1 is a branched chain alkyl consisting of 10 to 31 carbons; R 2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L 1 and L 2 are the same or different, each a linear alkylene of 1 to 20 carbons or a linear alkenylene of 2 to 20 carbons; X 1 is S or O; R 3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R 4 and R 5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

  描述的是一种化合物，其化学式为I，包括以下成分： R1为由10至31个碳组成的支链烷基化合物； R2为由2至20个碳组成的直链烷基、烯基或炔基； L1和L2相同或不同，每个为由1至20个碳组成的直链烷基或由2至20个碳组成的直链烯基； X1为S或O； R3为由1至6个碳组成的直链或支链烷基； R4和R5相同或不同，每个为氢或由1至6个碳组成的直链或支链烷基；或其药用可接受盐。
• [EN] BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DÉRIVÉS DE BENZODIOXANE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：ORION CORP

  公开号：WO2018002437A1

  公开（公告）日：2018-01-04

  Compounds of formula (I): wherein Ra and Rb are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.

  式(I)的化合物：其中Ra和Rb如权利要求中定义的，具有α2C拮抗活性，因此可用作α2C拮抗剂。
• [EN] QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE QUINOLÉINE ET DE QUINAZOLINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：STINGRAY THERAPEUTICS INC

  公开号：WO2020190912A1

  公开（公告）日：2020-09-24

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

  化合物及其制备和用作治疗或预防剂的方法，例如通过靶向Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。